Harpagoside

Harpagoside

1. Identity: Chemical and Botanical Characterization

Chemical Identity

Harpagoside is characterized as an iridoid glycoside, which is a product of the mevalonate pathway present in the metabolism of eukaryotes, archaea, and some bacteria. Its molecular formula is C₂₄H₃₀O₁₁, and it carries the PubChem Compound Identifier (CID) 5281542. Its molecular weight is 494.5 g/mol. The CAS Registry Number is 19210-12-9, and the EC Number is 242-881-6. In its purified form, harpagoside appears as a white crystalline powder that is easily soluble in methanol and water.

The iridane skeleton of harpagoside is monoterpenoid in origin and contains a cyclopentane ring fused to a six-membered oxygen heterocycle. The defining structural feature that distinguishes harpagoside from the closely related compound harpagide is a cinnamoyl ester group: cinnamoyl esterification at the 3-hydroxyl position of harpagide leads to the natural product harpagoside. Official compendia recognize harpagoside as a cinnamoylated iridoid glucoside, and use its content as a key marker compound for quality control of devil's claw preparations.

Botanical Sources

Harpagoside is a natural product primarily found in the plant Harpagophytum procumbens, also known as devil's claw. It is also the main bioactive component of medicinal plants including Radix Scrophulariae, Scrophularia ningpoensis, and Scrophularia buergeriana. Within the genus Harpagophytum, two species are recognized: H. procumbens (Burch.) DC. ex Meisn. and H. zeyheri Decne., currently divided into five subspecies, with introgression reported from overlapping habitats.

Harpagophytum procumbens is mainly found in the eastern and southeastern parts of Namibia, southern Botswana, and the Kalahari region of the Northern Cape, South Africa. It inhabits deep, sandy soils in areas with low annual rainfall (150–300 mm/year) and is a perennial, tuberous plant with annually produced creeping stems. The stems grow from a persistent primary tuber, and several secondary tubers — the harvested organs — grow from the primary tuber at the end of fleshy roots. The secondary root tubers of devil's claw are used in botanical drugs and supplements and are exported from Southern Africa, mainly Namibia.

The most prominent compounds identified in the root include iridoid glycosides — primarily harpagoside, harpagide, and procumbide — as well as phytosterols; phenylpropanoids such as verbascoside; triterpenes such as oleanolic acid, 3β-acetyloleanolic acid, and ursolic acid; flavonoids such as kaempferol and luteolin; unsaturated fatty acids; cinnamic acid; chlorogenic acid; and stachyose.

Common Forms and Preparations

Harpagophytum procumbens is used for a wide variety of health conditions in the form of infusions, decoctions, tinctures, powders, and extracts. For loss of appetite or dyspeptic complaints, the ESCOP dosage guideline specifies 0.5 g of the drug in decoction, three times daily, or equivalent preparations with corresponding bitterness value, or a tincture (1:10, 25% ethanol) at 3 ml. Standardized dried root extracts are the most widely used modern pharmaceutical form, with preparations typically standardized to a minimum harpagoside content. Once harvested, botanical differentiation between species and subspecies is virtually impossible; current official compendia do not distinguish between the two botanical sources of devil's claw but require compliance in terms of the marker compound harpagoside.

2. Traditional and Historical Use

Indigenous African Use

Harpagoside's parent plant has been used for centuries by the Khoisan people of southern Africa to treat diverse health disorders, including fever, diabetes, hypertension, and various blood-related diseases. Historically, the native Khoisan people harvested and utilized devil's claw (Harpagophytum procumbens) for childbirth, loss of appetite, and as a purgative, as well as for the treatment of various diseases and ailments such as menstrual problems, indigestion, bitter tonic, inflammation, febrifuge, and syphilis. In addition to the common local use for arthritis and pain, other ethnomedicinal uses include dyspepsia, fever, blood diseases, urinary tract infections, postpartum pain, sprains, sores, ulcers, and boils.

Introduction to Europe

It was not until the early 1900s that a German pioneer, Dr. Mehnert, observed a dramatically successful traditional treatment with the root tuber of this African herb, that it started to become known in Europe. From that point, devil's claw became a subject of both popular use and academic investigation in Europe, particularly in Germany and France. The widespread use of preparations of devil's claw and their generally accepted efficacy and safety was recognized by the introduction of an official monograph into both the 3rd edition of the European Pharmacopoeia and the current British Pharmacopoeia.

Traditional Chinese Medicine Use of Scrophularia ningpoensis

Scrophularia ningpoensis Hemsl (SNH) is a commonly used medicinal plant in East Asia; Scrophulariae Radix (SR) is the dried root and is one of the most commonly used medicinal parts, with a history of use in East Asia of more than 2,000 years. SR is used in traditional Chinese medicine for clearing away heat and cooling blood, nourishing Yin and reducing fire, and for detoxicating and resolving masses. Harpagide and harpagoside are the main secondary metabolites of S. ningpoensis, mainly found in the rhizome, and have high pharmaceutical value.

3. Key Constituents and Mechanisms of Action

Primary Active Compounds

Harpagoside and harpagide are the two main bioactive components found in the roots of Harpagophytum procumbens and have been implicated in its anti-inflammatory effects. Iridoid glycosides and phenylpropanoid glycosides have been the focus of phytochemical investigations, as the biological activity has been ascribed primarily to the iridoid glycosides — such as harpagoside and harpagide — which are known to possess anti-inflammatory activity. However, whether harpagoside is more than just a marker compound, and also the sole active compound, remains to be demonstrated; consequently, superiority of H. procumbens over H. zeyheri cannot be derived merely from harpagoside content.

NF-κB Pathway Inhibition

The mechanism of action of harpagoside, as one of the major components of Harpagophytum procumbens, has been investigated using human HepG2 hepatocarcinoma and RAW 264.7 macrophage cell lines. Harpagoside inhibited lipopolysaccharide-induced mRNA levels and protein expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). These inhibitions correlated with the suppression of NF-κB activation: pre-treating cells with harpagoside blocked the translocation of NF-κB into the nuclear compartments and degradation of the inhibitory subunit IκB-α. Furthermore, harpagoside dose-dependently inhibited LPS-stimulated NF-κB promoter activity in a gene reporter assay in RAW 264.7 cells, indicating that harpagoside interfered with the activation of gene transcription.

COX Inhibition

Harpagoside has been shown to inhibit both COX-1 and COX-2 activity (37.2% and 29.5%, respectively) and greatly inhibit NO production in vitro. Molecular docking studies have revealed that harpagoside and harpagide act as potential highly selective COX-2 inhibitors. Interactions were stabilized for harpagoside and harpagide within the active site of COX-2 by 7 and 10 hydrogen bonds, respectively. It has also been shown that the hydrolysed products of harpagoside and harpagide have more pronounced anti-inflammatory activity when compared to the unhydrolysed compounds.

Cytokine Modulation

Harpagoside has also been reported to inhibit the production of IL-1β, IL-6, and TNF-α by RAW 264.7 mouse macrophages. In primary human osteoarthritis chondrocytes, expression of IL-6 was highly induced by IL-1β, which was significantly inhibited by pre-treatment of cells with harpagoside. Harpagoside did not inhibit the IL-1β-induced activation of NF-κB and C/EBPβ transcription factors but suppressed the IL-1β-triggered induction, phosphorylation, and DNA binding activity of c-FOS, one of the main components of AP-1 transcription factors. Further, harpagoside significantly inhibited the expression of MMP-13 in OA chondrocytes under pathological conditions.

Leukotriene Pathway

The anti-inflammatory and analgesic properties of H. procumbens have been ascribed to inhibition of eicosanoid and nitric oxide (NO) biosynthesis, by altering expression and inhibition of cyclooxygenases (COX-1, COX-2) and lipoxygenases (LOX) and nitric oxide synthase (iNOS), and to altered expression of pro- and anti-inflammatory cytokines. Harpagoside, 8-p-coumarylharpagide, and related metabolites have been implicated as primary anti-inflammatory effectors. One study also found a correlation between serum harpagoside levels and leukotriene biosynthesis inhibition, suggesting a role in the lipoxygenase pathway as well.

Biosynthetic Pathway

The iridoid system arises from geraniol, which itself is synthesized from geranyl pyrophosphate (GPP) by geraniol diphosphate synthase. A P450-type enzyme, geraniol 8-hydroxylase, then hydroxylates geraniol at the 8-position to form 8-hydroxygeraniol. The diol then undergoes two oxidation steps catalyzed by 8-hydroxygeraniol dehydrogenase to form the dialdehyde, 8-oxogeranial. NADPH-catalyzed monoterpene cyclase then forms three possible iridodial isomers. Carboxylation followed by glycosylation leads to the glycoside. Subsequent decarboxylation and three P450-type oxidations lead to harpagide. Cinnamoyl esterification at the 3-hydroxyl position of harpagide leads to the natural product harpagoside. The complete biosynthetic pathway for harpagoside in the plant is not yet well-elucidated; while the principal steps are known, some intermediates remain hypothetical.

4. Scientific Evidence by Area of Use

4.1 Musculoskeletal Pain and Osteoarthritis

The primary medicinal uses of devil's claw are the management of arthritis, pain, and dyspepsia. An impressive number of clinical trials — the earlier being mostly observational, the more recent randomized, placebo-controlled studies, albeit of variable quality — indicate clinical efficacy and safety.

Systematic Reviews: A 2004 systematic review by Gagnier, Chrubasik, and Manheimer examined the effectiveness of Harpagophytum procumbens preparations for various forms of musculoskeletal pain. Twelve trials were included, with six investigating osteoarthritis, four low back pain, and three mixed-pain conditions. The authors concluded there was limited evidence for an ethanolic Harpagophytum extract containing less than 30 mg harpagoside per day in the treatment of knee and hip osteoarthritis.

A 2016 Cochrane review on herbal treatment for low back pain concluded that, with caveats for methodological quality, devil's claw has an impact on arthritic pain greater than placebo. An earlier review had concluded there was moderate evidence of benefit in osteoarthritic conditions as well as low back pain for devil's claw preparations delivering between 50–100 mg harpagoside per day.

Specific Clinical Trials: A randomized double-blind study of devil's claw on lower back pain was carried out over 4 weeks (Chrubasik et al., 1999). A characterized Harpagophytum extract (WS1351) was administered twice daily as a 600 mg (Group 1) or 1200 mg dose (Group 2) containing 50 and 100 mg of harpagoside, respectively, to 197 subjects with chronic back pain and current exacerbations with intense pain. Six of Group 1 and 10 of Group 2 were pain-free by the end of the trial. Analysis of the 183 subjects who completed the trial indicated that patients in the lower-dose group with less severe pain and without radiation or neurological deficit benefited more.

An open trial that enrolled patients with arthrosis of the hip, knees, fingers, or spine (n=630) showed significant improvements in pain after six months of treatment with devil's claw extract (3,000–9,000 mg/day). A fourth open trial enrolling patients with low back pain, osteoarthritic knee pain, or hip pain showed significant improvements in pain and mobility with only minor adverse events after eight weeks of treatment with Doloteffin devil's claw extract (60 mg harpagoside/day).

Results of several studies demonstrate that Harpagophytum extracts with more than 50 mg harpagoside per day are helpful in alleviating pain. Trials primarily targeted degenerative joint diseases as well as low back pain, and utilized a variety of methodological designs, with different preparations of devil's claw and daily doses of harpagoside varying from less than 30 to more than 100 mg.

The efficacy and safety of a devil's claw supplement were tested in a double-blind, randomized clinical trial in 122 adults suffering from osteoarthritis of the knee and hip. The results showed that Harpagophytum procumbens-containing capsules were comparable to the conventional anti-inflammatory drug used for osteoarthritis but had fewer side effects.

Overall evidence strength: The evidence for devil's claw (standardized to harpagoside content) in osteoarthritis and low back pain is moderate. Randomized controlled trials generally support efficacy over placebo, but methodological heterogeneity — varying doses, extract preparations, study durations, and patient populations — limits the strength of pooled conclusions. Despite extensive clinical evaluation, the active principles responsible for the clinical effect and the exact modes of action are not fully understood.

4.2 Dyspepsia and Appetite

The ESCOP supplement (2009) mentions as therapeutic indications for Harpagophytum root: symptomatic treatment of painful osteoarthritis, relief of low back pain, loss of appetite, and dyspepsia. ESCOP approves the use of devil's claw root for painful arthrosis, tendinitis, appetite loss, and indigestion/heartburn. The bitter iridoid constituents of the root — including harpagoside — are believed to stimulate gastric secretion, which forms the pharmacological basis for its digestive uses. However, robust clinical trial data specifically for harpagoside in dyspepsia are sparse; this indication is primarily supported by traditional use and pharmacological plausibility.

4.3 Neuroprotection (Preclinical)

Research has aimed to elucidate the effect of harpagoside (abbreviated HAR), an iridoid glycoside purified from the Chinese medicinal herb Scrophularia ningpoensis, on neurodegeneration induced by β-amyloid peptide (Aβ). HAR has been shown to exert neuroprotective effects against Aβ neurotoxicity. Harpagoside is a proposed neuroprotective iridoid active ingredient. A study aimed to investigate the effects of harpagoside on mitochondrial functions in rotenone-induced cell models of Parkinson's disease (PD).

Radix Scrophulariae (dried roots of Scrophularia ningpoensis Hemsl.) was reported to exert neuroprotection against cerebral ischemia and reperfusion injury through the ERK1/2 and p38 MAPK pathways. Furthermore, Scrophularia buergeriana extracts demonstrated neuroprotective properties against glutamate-induced cytotoxicity in SH-SY5Y cell models through antioxidant and anti-apoptotic mechanisms.

Harpagoside can decrease IκB-α protein phosphorylation and inhibit p65 protein translocation from the cytosol to the nucleus, thus suppressing NF-κB activation and reducing HIF-1α generation. These results suggest that the anti-inflammatory mechanism of harpagoside may be associated with the NF-κB signaling pathway.

Evidence strength: All neuroprotection findings for harpagoside are currently at the preclinical stage (cell culture and animal models). No controlled human clinical trials have been conducted in neurodegeneration indications. This area is considered highly preliminary.

4.4 Cardiovascular Effects (Preclinical)

In spontaneously beating Langendorff preparations of rabbit heart, a Harpagophytum procumbens methanolic extract caused a mild decrease in heart rate with a concomitant mild positive inotropic effect at lower doses, but a marked negative inotropic effect at higher doses. The coronary flow decreased at higher doses only. The negative chronotropic and positive inotropic effects of harpagoside were comparatively higher with respect to those of the full extract, whereas harpagide had only a slight negative chronotropic effect and a considerable negative inotropic one.

Evidence strength: Cardiovascular effects of harpagoside have been demonstrated only in isolated tissue and animal models. No dedicated human clinical trials have established cardiovascular benefits. These findings are primarily relevant to safety considerations regarding cardiac drug interactions (see Section 6).

4.5 Antimicrobial and Antioxidant Activity (Preclinical)

Scientific studies have revealed that H. procumbens exhibits analgesic, antioxidant, anti-diabetic, anti-epileptic, antimicrobial, and antimalarial activities, among others. These findings are based predominantly on in vitro studies. No confirmatory human clinical trials have been conducted for these indications, and their clinical relevance remains uncertain.

5. Body Systems and Health Areas

• Musculoskeletal system: The best-documented area of use; osteoarthritis (especially hip and knee), low back pain, tendinitis, and general musculoskeletal pain.
• Digestive system: ESCOP (2009) lists loss of appetite and dyspepsia as therapeutic indications alongside osteoarthritis and low back pain.
• Nervous system: Harpagoside is a proposed neuroprotective iridoid active ingredient; numerous studies have demonstrated neuroprotective effects of plant extracts containing harpagoside against damage in both cultured cell models and animal models. No human clinical evidence exists for neurological indications.
• Immune and inflammatory system: Several clinical trials have shown good tolerability and anti-inflammatory effects of Harpagophytum-containing products.
• Cardiovascular system: Harpagoside has demonstrated chronotropic and inotropic effects in preclinical settings; these are relevant primarily as safety considerations.

6. Dosage Forms and Reported Dosages

Harpagoside is not typically marketed or administered as an isolated pure compound in clinical practice. Commercially, it is the primary standardization marker for devil's claw root preparations. The following dosages are taken directly from published clinical research and regulatory monographs:

• General clinical research range: Devil's claw has been studied for low back pain, muscle pain, and osteoarthritis using daily doses of crude tuber up to 9 g, 1 to 3 g of extract, or harpagoside 50 to 100 mg.
• Chrubasik et al. (1999) RCT: Characterized Harpagophytum extract (WS1351) was administered at 600 mg (containing 50 mg harpagoside) or 1,200 mg (containing 100 mg harpagoside) twice daily to 197 subjects with chronic back pain.
• Doloteffin open trial: 60 mg harpagoside per day for eight weeks in patients with low back pain, osteoarthritic knee pain, or hip pain.
• Low back pain double-blind trials: Daily doses of devil's claw extracts in the range of 2,000–4,500 mg containing 30–57 mg of harpagoside for durations of 4–20 weeks.
• Recommended daily dose from pharmacopeial literature: 4.5–9 g crude drug, equivalent to more than 50 mg harpagoside.
• ESCOP (painful osteoarthritis): Daily dose of 2–5 g of the drug or equivalent dry extract prepared with water.
• Pharmacokinetic study design: A planned clinical pharmacokinetics study used a daily harpagoside dose of 100 mg, equivalent to dosing used in previous clinical studies that demonstrated beneficial effects and safety.
• Tendinitis RCT: Devil's claw extract (4,500 mg/day containing 30 mg harpagoside) showed significantly less pain in the treatment group compared with the placebo group.

7. Pharmacokinetics

Stability studies have investigated the release and stability of harpagoside in gastric and intestinal fluids, showing stability for 3 and 6 hours respectively. Harpagoside has been found to be of low bioavailability; a daily dose of 100 mg could not be detected in serum or urine in one study. Experiments simulating stomach conditions suggested that enteric-coated preparations for harpagoside may slow down acid hydrolysis.

Later analytical methods were able to detect harpagoside in plasma for up to 9 hours after administration. Pharmacokinetic data from equine studies (a model for which robust PK data exist) showed: C_max was found at 25.59 and 55.46 ng/ml, t_1/2 at 2.53 and 2.32 hours respectively, and t_max at 1 hour in both trials. AUC_0–inf was 70.46 and 117.85 ng·hr·ml⁻¹, respectively. A proportional relationship between dose, C_max, and AUC was observed.

While harpagoside is considered to contribute to the overall activity of devil's claw preparations, it is not yet fully understood which other compounds may also be of relevance. Furthermore, an investigation into the harpagoside content of commercially available devil's claw preparations revealed substantial variation, with contents often below the recommended daily dose of 4.5–9 g crude drug (equivalent to more than 50 mg harpagoside).

8. Safety Considerations and Drug Interactions

General Safety Profile

Clinically important toxicity has not been observed in limited, short-term use. Devil's claw is one of the best-documented phytomedicines; its mode of action is largely elucidated, and its efficacy and excellent safety profile have been demonstrated in a long list of clinical investigations. Common adverse effects reported are generally mild: adverse effects are rare, generally consisting of headache, tinnitus, or anorexia. Common side effects may include diarrhea, headache, feeling off balance, or an upset stomach.

Gastrointestinal Contraindications

The bitter substances Harpagophytum procumbens contains, which stimulate the production of stomach acid, can lead to gastroduodenal ulcers; this is why existing gastric or duodenal ulcers are considered a contraindication (ESCOP 2009). Patients with gallstones should also seek medical advice (WHO 2007).

Pregnancy, Lactation, and Pediatric Use

Due to a lack of data, Harpagophytum preparations are not recommended for pregnant and breastfeeding women; there are insufficient studies on genotoxicity, fertility, pregnancy, and breastfeeding (EMA 2021). Documented oxytocic adverse effects have been reported; use should be avoided in pregnancy. Due to a lack of data, use in children and adults under the age of 18 is not recommended.

Cardiovascular Drug Interactions

Devil's claw should not be used with antiarrhythmic, chronotropic, or inotropic medicines, and it is contraindicated in patients with gastric or duodenal ulcers because of the increase in gastric secretion caused by the bitter preparation. A case of devil's claw-induced hypertension has been documented. These cardiovascular concerns reflect the preclinical findings of chronotropic and inotropic activity attributable partly to harpagoside.

Anticoagulant Interactions

Alteplase and devil's claw both increase anticoagulation; caution and monitoring are advised. Devil's claw may have additive anticoagulant activity. Warfarin is the most common cardiovascular drug involved in herb interactions; devil's claw has been found to interact with warfarin, potentially resulting in over-anticoagulation.

Quality and Standardization Concerns

An investigation into the harpagoside content of commercially available devil's claw preparations revealed substantial variation, with contents often below the recommended daily dose. This variability means that products marketed as equivalent doses may deliver widely different amounts of harpagoside. Commercially available devil's claw products may contain material from both H. procumbens and H. zeyheri, and both species may vary in their pro- and anti-inflammatory constituents; this has undoubtedly contributed to the lack of agreement between published reports of efficacy.

References

• Wikipedia – Harpagoside
• Vlachojannis J. From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil's Claw (Harpagophytum spp.). Pharmaceuticals 2021; PMC8398729
• Gxaba N, Manganyi MC. The Fight against Infection and Pain: Devil's Claw – a Rich Source of Anti-Inflammatory Activity: 2011–2022. Molecules 2022; PMC9182060
• Huang TH et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation. J Ethnopharmacol 2006; PubMed 16203115
• Inaba K et al. Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. PMC5065736
• Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: A systematic review. BMC Complement Altern Med 2004; PMC520753
• EMA. Final Assessment Report on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix. European Medicines Agency, 2016.
• ScienceDirect Topics – Harpagophytum: Overview of Clinical Studies
• Li Y et al. Harpagoside ameliorates the amyloid-β-induced cognitive impairment in rats via up-regulating BDNF expression and MAPK/PI3K pathways. PubMed 26135675
• Cui Y et al. Radix Scrophulariae extracts (harpagoside) suppresses hypoxia-induced microglial activation and neurotoxicity. PMC4570756
• Protective effects of harpagoside on mitochondrial functions in rotenone-induced cell models of Parkinson's disease. PMC11843190
• Axmann S et al. Pharmacokinetics of harpagoside in horses after intragastric administration of a Devil's claw extract. J Vet Pharmacol Ther 2019; PMC7379497
• Drugs.com. Devil's Claw: Uses, Benefits & Dosage. Natural Products Database.
• PubChem – Harpagoside CID 5281542. National Library of Medicine.
• Chrubasik S. Effectiveness of devil's claw for osteoarthritis. Rheumatology 2002; 41(11):1332.
• Springer – Devil's claw (Harpagophytum procumbens): is the buzz in Google justified? Naunyn-Schmiedeberg's Archives of Pharmacology 2025.
• American Botanical Council HerbalGram – Anti-inflammatory Activity of Devil's Claw Reviewed.
• Vlachojannis J. From Bush Medicine to Modern Phytopharmaceutical. Pharmaceuticals (MDPI) 2021; 14(8):726.